Back to Insight

Are Functional Mushrooms Ready for Prime Time? 

Science is finally catching up to ancient tradition – and investors are watching.

By Gali Artzi, PhD

EXECUTIVE SUMMARY

Sifting through wellness and functional ingredient hype can baffle consumers and also challenge investors looking to find winners in the noise. But one category stands out for its ancient history and modern scientific potential: functional mushrooms, with centuries of traditional use and over 150 identified bioactive compounds. Today scientific credibility is steadily building behind species like reishi, lion’s mane, cordyceps, and turkey tail for their potential benefits in cognition, immunity, energy, and metabolic health. With continued rigorous study, functional mushrooms aren’t headed for 15 minutes of superfood fame, but towards a credible, scalable wellness category.

The market opportunity is compelling. In the U.S. alone the market for mushroom supplements and enhanced functional foods and beverages was worth about $1.1 billion in 2023, and continues to display 11-13% CAGR.1 Behind that are a number of factors. A surge in clinical research is catching up to centuries of traditional, reputable use – a potent combination of East meets West. Those health benefits are well aligned with consumers’ modern wellness priorities, from energy support to mental and metabolic health.2 Cultural shifts are moving towards optimizing health and biohacking, along with increasing consumer focus on clinical effectiveness. And functional mushrooms touch one more important nerve: resonating as real food amid a push against all things artificial.

But the sector does face headwinds, including complex growth protocols and regulations. There’s also a structural vulnerability: China produces an astounding 94% of the world’s edible mushrooms, creating supply chain risks amplified by recent geopolitical tensions. This extreme concentration exposes brands to pricing volatility, authenticity concerns, and contamination risks.3 4 5 Yet like familiar crops under supply chain stress, it’s also an opportunity for innovators to step in, with some already adopting vertically integrated models to control quality and supply chains.

Innovation and smart capital are responding. Investments in the sector are still limited but evolving through diverse funding mechanisms, with strategic partnerships complementing traditional private equity and specialized VC funds. Major CPGs and nutrition players, along with ingredient giants, represent likely acquirers: these companies often swap internal R&D for partnerships or acquisitions with proven innovators, paving scaling and exit routes for sector leaders.

Winners will be those who successfully navigate key differentiators, including clinical validation, IP, regulatory compliance, supply chain integrity, and consumer trust. That operational excellence coupled with a grasp of the market will position companies to scale, as the functional mushroom sector moves beyond niche to rapidly industrialize – with meaningful implications for wellness, nutrition, and global health ecosystems.

WHAT’S DRIVING THE MARKET?

In the U.S. alone the market for mushroom supplements and enhanced functional foods and beverages was worth about $1.1 billion in 2023, and continues to display 11-13% CAGR.6 Sales of mushroom supplements in the U.S. in particular saw a 75.8% increase over 2023, the biggest gain of any top 40 ingredient in mainstream retail channels.7 Behind it are several factors transforming functional mushrooms into a credible, scalable wellness category that taps into many of consumers’ biggest health priorities. First and foremost is the science, a bedrock of any health category with long-term legs. Clinical research around functional mushrooms is now catching up to centuries of use in Chinese medicine and Ayurveda, a compelling story of East meets West. That includes a surge in published studies on immunity, cognition, gut health, and even metabolic support. But there’s more to it: mushrooms are unusual in that many species have overlapping benefits. Lion’s mane for example can offer a trifecta of support as a mood stabilizer, gut health enhancer and nootropic. That notion of one-stop-shop wellness solutions is something few other natural ingredients can claim.

Then there’s consumer demand. A convergence of cultural and demographic shifts is pushing functional mushrooms into the mainstream. Their benefits are strongly aligned with growing priorities in health and wellness, including energy support, mental health, cognitive function, better sleep and metabolic health.8 Take the booming popularity of nootropics (cognitive enhancers) and adaptogens (for stress-management). Species like cordyceps and lion’s mane are gaining attention as natural brain boosters and energy enhancers, with the market for lion’s mane extract products forecast to grow by $181 million at a CAGR of 23.4% by 2029.9

If we go one step deeper, underlying those consumer priorities is what appears to be a tangible cultural shift: a mainstreaming of holistic health and biohacker culture, with people actively looking to optimize their health, rather than just treating illness when it strikes. Consumers are also seeking out clinical effectiveness. Americans in particular are prioritizing clinically-proven efficacy over clean ingredients across a range of categories, from nutrition and consumer goods to over-the-counter products.10 Finally, amid growing awareness (and wariness) around ultra-processed and artificial ingredients, functional mushrooms also have a distinct advantage in resonating as real food. 

Taken together, these factors are positioning the sector for long-term growth, and not short-term hype. In the next 2–3 years, we’re likely to see continued rapid expansion, with companies branching into more innovative formats like gummies, chocolates, skincare, and hot and cold beverages. Brands like Four Sigmatic, DIRTEA, and SuperMush already have offerings that go beyond traditional mushroom coffees, incorporating adaptogenic ingredients into products designed for improved focus, stress relief, and overall wellness. Growing consumer interest and investment in research are expected to lead to more scientifically validated formulations and standardized dosing – both crucial for boosting consumer confidence.

FUNCTION BEYOND FLAVOR

“Functional mushrooms” refer to those that are both edible and possess medicinal properties, and indeed many species have a long history of therapeutic use in traditional practices like Chinese medicine. Yet it wasn’t until the mid-to-late 19th century that scientific research gained traction.11 These fungi stand apart from the wellness crowd with some of nature’s most powerful bioactive compounds: over 150 identified, each linked in research and traditional knowledge to various health benefits. While the scientific evidence is still developing, early studies and clinical observations suggest promising effects that continue to attract interest from both researchers and consumers.12

Common Types13

Reishi (Ganoderma lucidum): Traditionally valued in Asian medicine and recognized as an adaptogen, reishi has been used to help manage physical and emotional stress while supporting immune function and overall wellbeing. Modern studies highlight its potential to enhance immune response, support metabolic balance including healthy blood sugar levels, and contribute to general resilience, making it a key focus in integrative health research.14 15 16

Lion’s mane (Hericium erinaceus): Recognizable by its distinctive white, shaggy appearance, lion’s mane has a long history in traditional Chinese medicine, particularly for neurological and digestive health. It’s now widely available in grocery stores, with research suggesting it may support brain and nerve function, promote cognitive health and neuroprotection, and enhance gastrointestinal wellness. 17 18 19 20 21

Turkey tail (Trametes versicolor): Distinguished by colorful, fan-shaped rings, turkey tail has had a longstanding role in East Asian healing practices, and is now recognized for its ability to support immune function and promote gut health. Rich in polysaccharides, antioxidants, and prebiotic fibers, it helps nourish beneficial gut flora while contributing to overall resilience. It has also been widely researched for its role in oncology, studied as a complementary approach to support patients undergoing conventional cancer therapies.22 23 24 25 26 27

Cordyceps (Cordyceps sinensis / Cordyceps militaris): Naturally rare and historically harvested from high-altitude regions, cultivated strains like Cordyceps militaris have enabled broader commercial production. Traditionally regarded as a vitality tonic, cordyceps is being studied for its potential to enhance energy and endurance, support sexual health, improve kidney function, and provide immunomodulatory benefits, which has attracted interest in integrative wellness research.28 29 30 31 32 33

Chaga (Inonotus obliquus): Known for its powerful antioxidant activity and its role in supporting immune function, chaga has been traditionally consumed as a bitter tea. Beyond its historical use, research suggests it may also help reduce oxidative stress, support gastrointestinal health, and contribute to overall resilience and vitality.34 35 36 37 38 39 40 41 42 43

Shiitake (Lentinula edodes): Shiitake has been widely enjoyed both for its culinary appeal and traditional use in medicine. It contains a range of valuable compounds, including beta-glucans, polysaccharides, lentinan, and eritadenine, contributing to its ability to enhance immune health and promote overall resilience.44 45 46 47 48 49

A Star Bioactive: Beta-Glucan

One bioactive compound stands out from the crowd and merits deeper understanding. Beta-glucans are a type of dietary fiber belonging to the class of polysaccharides: they occur naturally in the cell walls of functional mushrooms and foods like oats, wheat, and barley, and provide energy storage and powerful health benefits.50 So what makes them so prominent?

  • Abundance and consistency: Beta-glucans are a major, naturally abundant component in many edible and medicinal mushrooms, consistently found across species (e.g., shiitake, reishi, and maitake). That makes them easier and more cost-effective to extract and standardize, suited to manufacturing and quality control.51 52
  • Well-documented health benefits: Extensive scientific studies have validated beta-glucans for their immunomodulatory, anti-inflammatory, and antioxidant effects. Those have made them a go-to  bioactive marker for product efficacy in dietary supplements and functional foods.53
  • Standardization and regulatory acceptance: Relative chemical stability and well-established quantification methods allow manufacturers to create standardized extracts. In many markets, labelling based on beta-glucan content is common and provides a reliable benchmark for quality and potency.
  • Market demand and consumer familiarity: Beta-glucans are frequently mentioned on supplement labels, and consumers have grown accustomed to looking for this ingredient as proof of quality and efficacy.

PLAYERS IN THE FIELD

The sector operates through two primary business models: ingredient  manufacturers and B2B exporters that specialize in bulk extracts and powders (often sourcing from Asia and selling via distributors), and consumer-facing brands that retail to consumers, focusing on wellness, immunity and cognitive health.

With China dominating upwards of 90% of global supply, companies with vertical integration models may have a distinct advantage in sidestepping challenges and hedging risk. Companies like KÄÄPÄ Biotech, M2 Ingredients, and Nammex oversee cultivation, extraction, and packaging in house, offering superior quality control and traceability. Several players run hybrid models, combining B2B ingredient supply with B2C brands under vertically integrated operations to tighten quality control, traceability, and supply continuity, including M2 Ingredients/Om Mushrooms, Fungi Perfecti (Host Defense), Aloha Medicinals, MycoFormulas, and Cure Mushrooms. Non-integrated brands focus solely on branding and marketing, sourcing extracts from third-party growers, often in Asia, with minimal production control.

A Framework for Competitive Assessment

The broader functional ingredient space is increasingly crowded, often featuring marketing over substance. So how can we best assess the competitive landscape? A number of characteristics define positioning and maturity:

  • Origin of raw materials: Companies may cultivate mushrooms indoors using certified organic substrates (e.g., oats, sorghum, sustainably sourced wood), mainly in the U.S./EU for quality control and traceability. Or they can source wild/field-grown varieties from China’s biodiverse regions, which can introduce geopolitical, tariff, and regulatory uncertainties. Some small EU organic farms also supply limited volumes with high environmental standards.
  • Supply chain design: Models range from vertically integrated operations (cultivation through packaging under one roof, excellent traceability, strong resilience) to single-region sourcing (e.g., China or small EU farms), which face higher risks from trade disruptions, climate, and supplier dependency.
  • Quality assurance: Premium firms adhere to global standards with rigorous hygiene and audits. Most perform batch-level third-party testing for heavy metals, pesticides and microbes, but transparency varies. 
  • Traceability and transparency: An increasing number of companies implement batch-level tracking with digital access to CoAs, extraction data, and lab results via QR codes, enhancing consumer trust and regulatory compliance. But traceability levels remain uneven: some companies offer full visibility, others only minimal, and some none.
  • Regulatory readiness: Functional mushrooms rely on a layered certification framework. Core market access depends on food safety and quality standards like FDA cGMP and BRCGS, while USDA and EU Organic certifications strengthen clean-label positioning central to consumer trust. In the U.S., GRAS approvals and in Europe, Novel Foods authorizations are pivotal for expanding beyond supplements into foods and beverages. Regional pathways like India’s FSSAI, China’s NMPA, and Australia’s TGA remain underutilized but are critical for long-term global expansion. Together, these certifications determine not just compliance but the ability to scale across categories and markets. 54
  • Extraction techniques: Dual extraction (hot water + alcohol) remains the industry standard, ensuring recovery of both beta-glucans and triterpenes. Advanced methods like ultrasonic-assisted or enzymatic extraction improve yield and bioavailability while supporting clean-label claims. Whole biomass powders (fruiting bodies + mycelium) offer a broader compound matrix, though usually at lower concentrations of target actives, while emerging fermentation-based techniques provide scalable and consistent production of specific bioactives.
  • Fruiting body vs. mycelium content: Products vary in formulation: fruiting-body–only extracts are viewed as more potent and preferred in clinical settings, while full-spectrum powders (including mycelium) are marketed as holistic. The latter, however, may complicate labelling and regulatory compliance due to concerns over substrate residue.
  • Bioactive standardization: Nearly all companies report beta-glucan levels, but fewer measure other actives (e.g., ergothioneine, cordycepin, triterpenes). Advanced assays and third-party verification support efficacy claims and regulatory compliance. Inconsistent testing and batch variability remain common issues.

MAPPING THE CHALLENGES

Despite the compelling growth trajectory, structural challenges threaten to constrain industry development:

  • Supply chain vulnerabilities: Over 90% of mushroom cultivation is based in China, exposing the sector to geopolitical risks, tariffs, and inconsistencies in quality control. Indoor cultivation and vertical integration offer improvements but require significant capital.
  • Standardization and trust: Inconsistent testing methods for bioactive compounds create product variability and make efficacy claims tough to validate. Economically motivated adulteration, counterfeit products (especially on platforms like Amazon), and misleading labelling create consumer confusion, with few centralized labs for validating identity, purity, or potency.
  • Clinical validation gaps: Limited robust, standardized human clinical trials (especially outside of Japan and China) restrict health claims and credibility in Western markets.
  • Regulatory complexity: Divergent requirements across the U.S., EU, and Asia create friction in scaling internationally, especially for novel extracts requiring approvals. The ongoing industry debate over fruiting body vs. mycelium ingredients is slowing regulatory clarity and consumer education.

CLINICAL VALIDATION

Clinical validation is in initial stages, with several human trials exploring therapeutic effects of species like lion’s mane, reishi, and cordyceps on cognition, immunity, and metabolic health. Some randomized studies do report cognitive benefits, reductions in blood glucose, and immunomodulatory effects. Yet widespread clinical adoption is being slowed by funding limitations, inconsistent standardization, and variability in the content of bioactive compounds.

Selected Key Clinical Trials

Mushroom (Species)Study FocusDesign & DoseKey Outcomes
Lion’s mane(H. erinaceus)Cognitive function in MCIRCT; 30 older adults; 3 g/day for 16 weeksImproved cognitive scores; benefits receded after 4-week cessation55
Mood & sleep in menopausal womenDBPC; 30 women; ~2 g/day via cookies for 4 weeksReduced anxiety and improved sleep56
Psychomotor dexterity (pegboard test)Industry trial (Kaapa Mushrooms)Enhanced pegboard performance: no other cognitive effects reported57
Reishi(G. lucidum)Metabolic regulation in T2DMCrossover, 89 subjects, 50 g cooked mushrooms thrice daily↓ fasting glucose ~11%, ↓ LDL ~8%, no liver/kidney issues58
Cordyceps militaris (PeakO₂ blend)Aerobic performanceRCT; healthy adults; 4 g/day; 1–3 weeksNo significant effects after 1 week; after 3 weeks, significant improvements in VO₂ max, ventilatory threshold, time to exhaustion, and relative peak power59  

Barriers to Clinical Validation

  • Funding constraints: Unlike pharmaceuticals that attract big R&D investments, natural products like mushrooms lack robust funding, making it difficult to conduct large, multi-centre randomized controlled trials.60
  • ‘Natural’ complexity: Natural products can contain hundreds of different compounds that may be synergistic, antagonistic, or interact in complex ways, meaning more complexity in pinpointing mechanisms of action and predict potential side effects or interactions.61
  • Variability in raw material: Differences in mushroom species, growing conditions, harvest timing, and extraction methods can lead to inconsistent chemical profiles. This lack of standardization makes it tough to replicate study results or establish reliable dosage guidelines. Many trials are instead conducted not on mushrooms, but on standardized  extracts rich in a specific compound.62

MASTERING REGULATION FOR MARKET ACCESS

Regulatory frameworks vary across the map, shaping how products are developed, marketed, and distributed. The EU prioritizes traceability, safety, and ecological compliance, while the U.S. currently offers a more commercially flexible but less standardized environment, and Asia is shifting traditional medicinal use toward evolving global standards.

European Union: Science-Based and Traceability-Driven

  • Pre-market authorization: Novel species or extraction methods require EFSA approval under the Novel Foods Regulation. Traditional species like shiitake may be sold as food supplements, but must comply with relevant directives. 
  • Labelling: Clear, descriptive names are needed (e.g., “mushroom protein powder” or “mycelium extract”), along with legally required information for novel foods, nutrition/health claims, and organic labelling.63 *See Appendix A for EU labelling example 
  • Safety controls: Strict thresholds for mycotoxins, heavy metals, and microbial pathogens. DNA barcoding is mandated in markets like Italy and Spain for species authentication.64 65 66
  • Sustainability: Biodiversity is protected through PEFC-certified wild harvesting, habitat restrictions, and gene bank preservation of medicinal strains. Invasive species are tightly regulated.
  • Traceability: Products must meet batch-level traceability and map cultivation areas to ensure deforestation-free sourcing.67 68

United States: Flexible and Fast-to-Market

  • DSHEA framework: Functional mushrooms are regulated as dietary supplements, not drugs. No pre-market approval is needed unless products involve novel extracts (triggering NDI filings).
  • GRAS pathway: Ingredients can be self-affirmed as GRAS (Generally Recognized as Safe) through a company-led expert panel, without requiring FDA review or oversight. This enables faster market entry but lacks the regulatory validation and transparency of the FDA-notified GRAS pathway. The U.S. administration has however signalled a desire to close the self-affirmed pathway, which could make it a riskier route. 
  • Claims & labelling: Disease treatment claims are prohibited; structure/function claims are allowed (e.g., “supports immunity”), but must be substantiated by clinical data to withstand regulatory scrutiny and build consumer trust. Labels may declare “mushroom blend” without specifying origin or species.
  • Safety controls: Manufacturers must follow GMP standards, but there is no mandatory contaminant testing or traceability requirement at the federal level.

Asia: Traditional Use Meets Global Standards69

  • Global alignment: As export ambitions grow, these markets are adapting regulatory structures to better align with international standards on clinical validation, product safety, and labelling.
  • Integrated traditional systems: Countries like China and South Korea incorporate functional mushrooms into national pharmacopeias, supported by centuries of traditional medicinal use.
  • Variability: Frameworks differ significantly between countries, with some adopting China’s rigor (e.g., CFDA) while others remain relatively underdeveloped.

*See Appendix B for further detail on regulatory differences and market implications

FOLLOWING THE MONEY

Venture capital, private equity, and strategic investors have all given growing attention to the sector, driven by rising consumer demand for natural health. Investment activity is now concentrated in early-stage companies with strong technical capabilities, wellness positioning, and defensible IP. Corporate acquisitions and strategic partnerships are also paving the way for scalable exits, supply chain integration, and commercialization of mushroom-derived therapeutics and supplements.

Within venture capital specialized investors are leading the charge, with Five Seasons Ventures and PeakBridge’s FoodSparks® backing flagship brands like Spacegoods (lion’s mane & adaptogen powders) and KÄÄPÄ Biotech (European functional mushroom extracts). Celebrity endorsements are driving mainstream attention, with Alice’s mushroom chocolates securing seed funding from L Catterton, Mandi Ventures, and Fourward Ventures, backed by names like Zac Efron and Pedro Pascal. Other popular categories are also attracting capital: Clevr Blends raised €2.52M for mushroom lattes, while Mushröm closed €2.13M for protein powders.

Deal flow spans the funding spectrum, revealing distinct investment theses at each stage:70

Testing the waters early ($0.1M-$1M): Companies like French Mush (€0.14M), Everystate (€0.35M), BRĒZ (€0.24M), Alice Foods (undisclosed), and Below Farm (undisclosed) represent entrepreneurs testing format innovation and consumer adoption, often through angel rounds or small seed checks.

Proven traction ($1M-$5M): Barcode’s €4.32M, Kaapa Biotech’s $3.6M, Clevr Blends’ €2.52M, and Mushröm’s €2.13M seed rounds, along with similar deals from Dirtea (undisclosed), B.T.R. NATION (undisclosed), and ZOOZ Drinks (€1.47M) show investors backing companies with demonstrated market fit.

Expansion capital ($10M+): M2 Ingredients exemplifies the capital intensity required for vertical integration, having raised $33M across three rounds. Most recently was a $25.8M  Series B to build its vertically integrated mycelium/fruiting-body facility while supporting clinical trials.

Beyond the traditional VC, hybrid funding models are emerging that combine investment with operational support. Applied Food Sciences invested $2.5M in KÄÄPÄ Biotech while simultaneously integrating them into their supply chain – a model that provides both capital and market access.71 Meanwhile traditional PE players like Paine Schwartz Partners and British Columbia Investment Management Corporation have taken minority stakes in established players like Monterey Mushrooms, reflecting institutional confidence in the sector’s long-term prospects.

For companies looking beyond investment, the most likely end game involves large CPGs and B2B ingredient players. Among those are Nestlé Health Science, Unilever, Abbott Nutrition, Herbalife, Amway, and Danone, alongside global ingredient and specialty nutrition companies like Kerry Group, IFF, DSM-Firmenich, and ADM. Large corporates have traditionally low R&D spend (compared to pharma or software, for example), along with a lower tolerance for risk in innovation. One option often pursued is partnerships with proven innovators or acquisitions, which can in turn provide a strong route for sector leaders to scale or exit.

The Takeaways: What it Takes to Win

Functional mushrooms represent a convergence of scalable ingredient innovation and tangible health outcomes, aligning with PeakBridge’s mission to back technologies that deliver long-term positive impact across nutrition and wellness. That success depends on a combination of operational excellence and scientific credibility. Winners will be those who master key differentiators:

  • Clinical validation: Build trust through robust studies and efficacy claims 
  • Bioactive potency: Secure competitive edge through consistent, measurable active compounds 
  • IP as a strategic asset: Strengthen efficacy claims and create barriers to entry via patents on strains, formulations, cultivation systems, and dosing methods 
  • Regulatory compliance: Meet global standards for quality and market access 
  • Supply chain control: Hedge against risk with strong contamination prevention and traceability

The market remains dominated by seed and series A rounds, suggesting that while consumer adoption is accelerating, the industry is still early in its commercial lifecycle.72 The presence of experienced global funds indicates growing belief in risk-adjusted returns, especially for companies pairing product-market fit with clinical evidence and IP defensibility.73 Companies that successfully integrate those key differentiators – navigating the intersection of traditional wellness wisdom and modern commercial requirements – will be best positioned to scale and capture the significant market opportunity ahead.

APPENDIX

A. Example: Labelling for EU Regulations

Food name (Regulation 1169/2011)

  • Legal name: Dried powder of Hericium erinaceus (lion’s mane)
  • Descriptive name (if needed): Mushroom powder made from the fruiting body of lion’s mane (Hericium erinaceus)

Ingredients

  • 100% organic lion’s mane mushroom powder (Hericium erinaceus fruiting body)

Allergens (if applicable)

  • May contain traces of gluten, nuts, or soy 

Net quantity

  • e.g. 100 g

Date of minimum durability

  • Best before: 30/06/2026

Special storage conditions

  • Store in a cool, dry place, away from sunlight.

Name and address of the FBO (Food Business Operator)

  • Mushroom Naturals GmbH, Königstraße 45, 70173 Stuttgart, Germany

Country of origin

  • Non-EU Agriculture (China) (as required under EU Organic Regulation 2018/848)

Instructions for use

  • Mix 1 tsp (2 g) daily into smoothies, coffee, or food.

Nutrition declaration (optional if single-ingredient & no claims, but often included)

  • Per 100 g: Energy 1230 kJ / 295 kcal, Protein 21 g, Carbohydrate 34 g (of which sugars 2 g), Fibre 24 g, Fat 2 g

B. Regulatory Differences and Market Implications74

Key StepEU RequirementsUS Requirements
Pre-Market ApprovalPre-market approval required for health claimsNo pre-market approval, post-market surveillance
Contaminant Testing(heavy metals, pesticide residues and microbial contamination)Limits for heavy metals are generally stricter, and products must be tested for compliance. Regulations also require more extensive testing for pesticide residues in supplements and functional foods. While both markets mandate microbial testing to ensure products are free from harmful bacteria or fungi, the EU imposes more detailed testing procedures than the U.S.Dietary supplements must comply with set limits for contaminants such as lead, arsenic, and cadmium, adhere to maximum residue limits for pesticides in food products, and undergo microbial testing to ensure they are free from harmful bacteria or fungi.
LabellingMust be EFSA approved before usageMust comply with FDA guidelines for health claims
Deforestation ChecksGeolocation mapping to plot levelNo equivalent federal requirements
Health Claim Approval ProcessStringent and time intensive processTime-consuming, complex process
Ingredient ApprovalMust be listen on EU’s approved ingredient listIngredients need to be safe, but no pre-market approval
Nutritional InformationMandatory, with additional specifics on certain nutrientsMandatory for all supplements
Market SurveillanceStrict pre-market inspection and regulatory checksPost-market, random checks, and audits 
  1. Nutrition Business Journal Mushroom Market Report 2024 ↩︎
  2. Nutrition Business Journal Mushroom Market Report 2024; McKinskey & Company “The trends defining the $1.8 trillion global wellness market in 2024” ↩︎
  3. Liu, J., Sun, J., He, R., Xia, J., & He, P. (2024). The situation of counterfeited and mislabeled commercialized edible mushrooms in China and the development of possible controls. Foods, 13(19), Article 3097. https://www.mdpi.com/2304-8158/13/19/3097 ↩︎
  4. https://www.nutraceuticalsworld.com/standardizing-mushroom-supplements/ ↩︎
  5. https://impactbuilders.eu/2025/05/21/rethinking-mushroom-sourcing-in-a-china-dependent-world/ ↩︎
  6. Nutrition Business Journal Mushroom Market Report 2024 ↩︎
  7. “U.S. Sales of Herbal Supplements Increase 5.4% in 2024,” American Botanical Council, SPINS, Nutrition Business Journal ↩︎
  8. Nutrition Business Journal Mushroom Market Report 2024; McKinskey & Company “The $2 trillion global wellness market gets a millennial and Gen Z glow-up” ↩︎
  9. Source: Technavio Lions Mane Mushroom Extract Products Market 2025-2029
    https://www.technavio.com/report/lions-mane-mushroom-extract-products-market-industry-analysis
    ↩︎
  10. McKinskey & Company “The trends defining the $1.8 trillion global wellness market in 2024” ↩︎
  11. https://ommushrooms.com/blogs/blog/what-are-functional-mushrooms-m2?srsltid=AfmBOoq9loHNPdPwDv73P5h-7Tb8ntFdMBh_ce_qpchflIDttj3f-MMU ↩︎
  12. https://ancientandbrave.earth/blogs/news/introduction-to-the-healing-power-of-functional-mushrooms?srsltid=AfmBOoqmWNMTYg60VvCN1itusYqM6ctMgY4W0icamtCbwQArGhFbIjqE ↩︎
  13. https://www.goodrx.com/well-being/supplements-herbs/functional-mushrooms?srsltid=AfmBOoo9_UaGZ5qiNJLq8LE6PIieUrZpeu7obqJvse9_o5y-H9TyXoTn ↩︎
  14. Wang, X., & Lin, Z. (2019). Immunomodulating effect of Ganoderma (Lingzhi) and possible mechanism. In Advances in Experimental Medicine and Biology (Vol. 1182, pp. 1–37). Springer. https://doi.org/10.1007/978-981-32-9421-9_1 ↩︎
  15.  Iser-Bem, P. N., Lobato, T. B., Alecrim-Zeza, A. L., Oliveira, L. C. dos S., Passos, M. E. P., Manuel, R., Diniz, V. L. S., Correa, I. S., Oliveira, S. P., Silva, E. B., … & Gorjão, R. (2024). Ganoderma lucidum dry extract supplementation modulates T lymphocyte function in older women. British Journal of Nutrition, 132(2), 130–140. https://doi.org/10.1017/S0007114524001144 ↩︎
  16. Gundermann, D., Ghatak, S., Wilcox, M. L., Maki, K. C., & Pauli, E. K. (2025). A randomized, double-blind, placebo-controlled study to investigate the effects of a reishi mushroom and ashwagandha supplement on perceived stress in healthy adults. Current Developments in Nutrition, 9(Suppl 2), Article 106183. https://cdn.nutrition.org/article/S2475-2991(25)01643-9/fulltext ↩︎
  17. Narayanan, M., Reddy, K. M., & Marsicano, E. (2018). Peptic ulcer disease and Helicobacter pylori infection. Missouri Medicine, 115(3), 219–224. PMCID: PMC6140150. https://pmc.ncbi.nlm.nih.gov/articles/PMC6140150/ ↩︎
  18. Ren, Y., Geng, Y., Du, Y., Li, W., Lu, Z.-M., Xu, H.-Y., Xu, G.-H., Shi, J.-S., & Xu, Z.-H. (2018). Polysaccharide of Hericium erinaceus attenuates colitis in C57BL/6 mice via regulation of oxidative stress, inflammation-related signaling pathways and modulating the composition of the gut microbiota. The Journal of Nutritional Biochemistry, 57, 67–76. https://pubmed.ncbi.nlm.nih.gov/29677563/ ↩︎
  19. Chen, D., Yang, X., Zheng, C., Yang, J., Tang, X., Chen, J., Ou, S., & Xie, Y. (2017). Extracts from Hericium erinaceus relieve inflammatory bowel disease by regulating immunity and gut microbiota. Oncotarget, 8(49), 85,838–85,857. https://pubmed.ncbi.nlm.nih.gov/29156761/ ↩︎
  20.  Li, I.-C., Chang, H.-H., Lin, C.-H., Chen, W.-P., Lu, T.-H., Lee, L.-Y., Chen, Y.-W., Chen, Y.-P., Chen, C.-C., & Lin, D.-P.-C. (2020). Prevention of Early Alzheimer’s Disease by erinacine A-enriched Hericium erinaceus mycelia: Pilot double-blind placebo-controlled study. Frontiers in Aging Neuroscience, 12, 155. https://pmc.ncbi.nlm.nih.gov/articles/PMC7283924/ ↩︎
  21. Chiu, C.-H., Chyau, C.-C., Chen, C.-C., Lee, L.-Y., Chen, W.-P., Liu, J.-L., Lin, W.-H., & Mong, M.-C. (2018). Erinacine A-enriched Hericium erinaceus mycelium produces antidepressant-like effects through modulating BDNF/PI3K/Akt/GSK-3β signaling in mice. International Journal of Molecular Sciences, 19(2), 341. https://pubmed.ncbi.nlm.nih.gov/29364170/ ↩︎
  22. Pilkington, K., Wieland, L. S., Teng, L., Jin, X. Y., Storey, D., & Liu, J. P. (2022). Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer. Cochrane Database of Systematic Reviews, 11, CD012053. https://pubmed.ncbi.nlm.nih.gov/36445793/ ↩︎
  23. Okuno, S., Miyamae, M., Sekine, I., Kudo, K., Tsuruta, M., et al. (2016). A randomized phase III trial comparing surgery + UFT + PSK to surgery alone for stage II rectal cancer: JFMC 37-7 trial. International Journal of Clinical Oncology, 21(3), 511–518. https://pmc.ncbi.nlm.nih.gov/articles/PMC5754396/ ↩︎
  24.  Multi-center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO). (2018). Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG). Surgery Today, 48(1), 66–72. https://pubmed.ncbi.nlm.nih.gov/28634730/ ↩︎
  25.  Ma, Y., Wu, X., Yu, J., Zhu, J., Pen, X., & Meng, X. (2018). Can polysaccharide K improve therapeutic efficacy and safety in gastrointestinal cancer? A systematic review and network meta-analysis. Oncotarget, 9(102), 36,574–36,589. https://pmc.ncbi.nlm.nih.gov/articles/PMC5687673/ ↩︎
  26. Awadasseid, A., Hou, J., Gamallat, Y., Xueqi, S., Eugene, K. D., Hago, A. M., Bamba, D., Meyiah, A., Gift, C., & Yi, X. (2017). Purification, characterization, and antitumor activity of a novel glucan from the fruiting bodies of Coriolus versicolor. PLOS ONE, 12(2), e0171270. https://pmc.ncbi.nlm.nih.gov/articles/PMC5298263/ ↩︎
  27. Roca-Lema, D., Martínez-Iglesias, O., Fernández de Ana Portela, C., Rodríguez-Blanco, A., Valladares-Ayerbes, M., Díaz-Díaz, A., Casas-Pais, A., Prego, C., & Figueroa, A. (2019). In vitro anti-proliferative and anti-invasive effect of polysaccharide-rich extracts from Trametes versicolor and Grifola frondosa in colon cancer cells. International Journal of Medical Sciences, 16(2), 231–240. https://pmc.ncbi.nlm.nih.gov/articles/PMC6367522/ ↩︎
  28. Li, J., Cai, H., Sun, H., Qu, J., Zhao, B., Hu, X., Li, W., Qian, Z., Yu, X., Kang, F., Wang, W., Zou, Z., Guo, B., & Xu, K. (2020). Extracts of Cordyceps sinensis inhibit breast cancer growth by promoting M1 macrophage polarization via NF-κB pathway activation. Journal of Ethnopharmacology, 260, 112969. https://www.sciencedirect.com/science/article/abs/pii/S0378874120308370?via%3Dihub ↩︎
  29. Park, J. G., Son, Y.-J., Lee, T. H., Baek, N. J., Yoon, D. H., Kim, T. W., Aravinthan, A., Hong, S., Kim, J.-H., Sung, G.-H., & Cho, J. Y. (2017). Anticancer efficacy of Cordyceps militaris ethanol extract in a xenografted leukemia model. Evidence-Based Complementary and Alternative Medicine, 2017, Article 8474703. https://pmc.ncbi.nlm.nih.gov/articles/PMC5518515/ ↩︎
  30.  Guo, Z., Chen, W., Dai, G., & Huang, Y. (2020). Cordycepin suppresses the migration and invasion of human liver cancer cells by downregulating the expression of CXCR4. International Journal of Molecular Medicine, 45(1), 141–150. https://pmc.ncbi.nlm.nih.gov/articles/PMC6889938/ ↩︎
  31. Lan, Y.-H., Lu, Y.-S., Wu, J.-Y., Lee, H.-T., & et al. (2022). Cordyceps militaris reduces oxidative stress and regulates immune T cells to inhibit metastatic melanoma invasion. Antioxidants, 11(8), 1502. https://pmc.ncbi.nlm.nih.gov/articles/PMC9404731/ ↩︎
  32. Zhang, Z., Li, K., Zheng, Z., & Liu, Y. (2022). Cordycepin inhibits colon cancer proliferation by suppressing MYC expression. BMC Pharmacology and Toxicology, 23, 12. https://pmc.ncbi.nlm.nih.gov/articles/PMC8817531/ ↩︎
  33. Jo, E., Jang, H.-J., Shen, L., Yang, K. E., Jang, M. S., Huh, Y. H., Yoo, H. S., Park, J., Jang, I. S., & Park, S. J. (2020). Cordyceps militaris exerts anticancer effect on non–small cell lung cancer by inhibiting Hedgehog signaling via suppression of TCTN3. Integrative Cancer Therapies, 19, Article 1534735420923756. https://pmc.ncbi.nlm.nih.gov/articles/PMC7265736/ ↩︎
  34. Kim, Y. R. (2005). Immunomodulatory activity of the water extract from medicinal mushroom Inonotus obliquus. Mycobiology, 33(3), 158–162. https://pmc.ncbi.nlm.nih.gov/articles/PMC3774877/ ↩︎
  35. Choi, S. Y., Hur, S. J., An, C. S., Jeon, Y. H., Jeoung, Y. J., Bak, J. P., & Lim, B. O. (2010). Anti-inflammatory effects of Inonotus obliquus in colitis induced by dextran sodium sulfate. Journal of Biomedicine and Biotechnology, 2010, Article 943516. https://onlinelibrary.wiley.com/doi/10.1155/2010/943516 ↩︎
  36. Mishra, S.K., Kang, J.H., Kim, D.K., Oh, S.H., & Kim, M.K. (2012). Orally administered aqueous extract of Inonotus obliquus ameliorates acute inflammation in dextran sulfate sodium (DSS)-induced colitis in mice. Journal of Ethnopharmacology, 143(2), 524–532. https://pubmed.ncbi.nlm.nih.gov/22819687/ ↩︎
  37. Zhao, F., Xia, G., Chen, L., Zhao, J., Xie, Z., Qiu, F., & Han, G. (2016). Chemical constituents from Inonotus obliquus and their antitumor activities. Journal of Natural Medicines, 70(4), 721–730. https://pubmed.ncbi.nlm.nih.gov/27180084/ ↩︎
  38. Chung, M. J., Chung, C.-K., Jeong, Y., & Ham, S.-S. (2010). Anticancer activity of subfractions containing pure compounds of Chaga mushroom (Inonotus obliquus) extract in human cancer cells and in BALB/c mice bearing Sarcoma-180 cells. Nutrition Research and Practice, 4(3), 177–182. https://pubmed.ncbi.nlm.nih.gov/20607061/ ↩︎
  39. Lee, H. S., Kim, E. J., & Kim, S. H. (2015). Ethanol extract of Inonotus obliquus (Chaga mushroom) induces G₁ cell cycle arrest in HT-29 human colon cancer cells. Nutrition Research and Practice, 9(2), 111–116. https://pubmed.ncbi.nlm.nih.gov/25861415/ ↩︎
  40. Ma, L., Chen, H., Dong, P., & Lu, X. (2013). Anti-inflammatory and anticancer activities of extracts and compounds from the mushroom Inonotus obliquus. Food Chemistry, 139, 503–508. https://www.sciencedirect.com/science/article/abs/pii/S0308814613000526 
    ↩︎
  41. Youn, M.-J., Kim, J.-K., Park, S.-Y., Kim, Y., Kim, S.-J., Lee, J.-S., Chai, K.-Y., Kim, H.-J., Cui, M.-X., So, H. S., Kim, K.-Y., & Park, R. (2008). Chaga mushroom (Inonotus obliquus) induces G₀/G₁ arrest and apoptosis in human hepatoma HepG2 cells. World Journal of Gastroenterology, 14(4), 511–517. https://pubmed.ncbi.nlm.nih.gov/18203281/ ↩︎
  42.  Arata, S., Watanabe, J., Maeda, M., Yamamoto, M., Matsuhashi, H., Mochizuki, M., Kagami, N., Honda, K., & Inagaki, M. (2016). Continuous intake of the Chaga mushroom (Inonotus obliquus) aqueous extract suppresses cancer progression and maintains body temperature in mice. Heliyon, 2(5), e00111. https://doi.org/10.1016/j.heliyon.2016.e00111 ↩︎
  43. Lee, S. H., Hwang, H. S., & Yun, J. W. (2009). Antitumor activity of water extract of a mushroom, Inonotus obliquus, against HT-29 human colon cancer cells. Phytotherapy Research, 23(12), 1784–1789. https://pubmed.ncbi.nlm.nih.gov/19367670/ ↩︎
  44. Xu, X., Yang, J., Luo, Z., & Zhang, X. (2015). Lentinula edodes-derived polysaccharide enhances systemic and mucosal immunity by spatial modulation of intestinal gene expression in mice. Food Function, 6(6), 2068–2080. https://pubmed.ncbi.nlm.nih.gov/26034783/ ↩︎
  45. Dai, X., Stanilka, J. M., Rowe, C. A., Esteves, E. A., Nieves, C. J., Spaiser, S. J., Christman, M. C., Langkamp-Henken, B., & Percival, S. S. (2015). Consuming Lentinula edodes (shiitake) mushrooms daily improves human immunity: A randomized dietary intervention in healthy young adults. Journal of the American College of Nutrition, 34(6), 478–487. https://pubmed.ncbi.nlm.nih.gov/25866155/ ↩︎
  46. Kabir, Y., Yamaguchi, M., & Kimura, S. (1987). Effect of shiitake (Lentinus edodes) and maitake (Grifola frondosa) mushrooms on blood pressure and plasma lipids of spontaneously hypertensive rats. Journal of Nutritional Science and Vitaminology, 33(5), 341–346. https://pubmed.ncbi.nlm.nih.gov/3443885/ ↩︎
  47. Bak, W. C., Park, J. H., Park, Y. A., & Ka, K. H. (2014). Determination of glucan contents in the fruiting bodies and mycelia of Lentinula edodes cultivars. Mycobiology, 42(3), 301–304. https://pubmed.ncbi.nlm.nih.gov/25346611/ ↩︎
  48. Phillips, K. M., Ruggio, D. M., Horst, R. L., Minor, B., Simon, R. R., Feeney, M. J., Byrdwell, W. C., & Haytowitz, D. B. (2011). Vitamin D and sterol composition of 10 types of mushrooms from retail suppliers in the United States. Journal of Agricultural and Food Chemistry, 59(14), 7841–7853. https://pubmed.ncbi.nlm.nih.gov/21663327/ ↩︎
  49. Guillamón, E., García-Lafuente, A., Lozano, M., D’Arrigo, M., Rostagno, M. A., Villares, A., & Martínez, J. A. (2010). Edible mushrooms: Role in the prevention of cardiovascular diseases. Fitoterapia, 81(7), 715–723. https://doi.org/10.1016/j.fitote.2010.06.005 ↩︎
  50. https://www.acslab.com/mushrooms/beta-glucans#what-are-beta-glucans ↩︎
  51. Łysakowska, P., Sobota, A., & Wirkijowska, A. (2023). Medicinal mushrooms: Their bioactive components, nutritional value and application in functional food production—A review. Molecules, 28(14), 5393. https://www.researchgate.net/publication/372344884_Medicinal_Mushrooms_Their_Bioactive_Components_Nutritional_Value_and_Application_in_Functional_Food_Production-A_Review ↩︎
  52.  https://hifasdaterra.com/en/medicinal-mushrooms/active-biomolecules/ ↩︎
  53. Venturella, G., Ferraro, V., Cirlincione, F., Gargano, M. L., & Jeewon, R. (2021). Medicinal mushrooms: Bioactive compounds, use, and clinical trials. International Journal of Molecular Sciences, 22(2), 634. https://pmc.ncbi.nlm.nih.gov/articles/PMC7826851/ ↩︎
  54. PeakBridge Analysis ↩︎
  55. Mori, K., Inatomi, S., Ouchi, K., Azumi, Y., & Tuchida, T. (2009). Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: A double-blind placebo-controlled clinical trial. Phytotherapy Research, 23(3), 367–372. https://doi.org/10.1002/ptr.2634 ↩︎
  56. Nagano, M., Shimizu, K., Kondo, R., Hayashi, C., Sato, D., Kitagawa, K., & Ohnuki, K. (2010). Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomedical Research, 31(4), 231–237. https://opis-cdn.tinkoffjournal.ru/mercury/lion-mane-hericium-erinaceus-research.tflbd2iobvz6..pdf ↩︎
  57. Surendran, G., Saye, J., Mohd Jalil, S. B., Spreadborough, J., Duong, K., Shatwan, I. M., Lilley, D., Heinrich, M., Dodd, G. F., & Surendran, S. (2025). Acute effects of a standardised extract of Hericium erinaceus (Lion’s Mane mushroom) on cognition and mood in healthy younger adults: A double-blind randomised placebo-controlled study. Frontiers in Nutrition, 12, 1405796. https://doi.org/10.3389/fnut.2025.1405796 ↩︎
  58. Venturella, G., Ferraro, V., Cirlincione, F., & Gargano, M. L. (2021). Medicinal mushrooms: Bioactive compounds, use, and clinical trials. International Journal of Molecular Sciences, 22(2), 634. https://doi.org/10.3390/ijms22020634 ↩︎
  59. Hirsch, K. R., Smith-Ryan, A. E., Roelofs, E. J., Trexler, E. T., & Mock, M. G. (2016). Cordyceps militaris improves tolerance to high intensity exercise after acute and chronic supplementation. Journal of Dietary Supplements, 14(1), 42–53. https://doi.org/10.1080/19390211.2016.1203386 ↩︎
  60. https://www.mycostories.com/post/functional-mushrooms-and-the-barriers-for-clinical-research ↩︎
  61. https://www.mycostories.com/post/functional-mushrooms-and-the-barriers-for-clinical-research ↩︎
  62. https://www.mycostories.com/post/functional-mushrooms-and-the-barriers-for-clinical-research ↩︎
  63. Molitorisová, A., Monaco, A., & Purnhagen, K. P. (2021). An analysis of the regulatory framework applicable to products obtained from mushroom and mycelium. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3955899 ↩︎
  64. Giusti, A., Tinacci, L., Verdigi, F., Narducci, R., Gasperetti, L., & Armani, A. (2022). Safety and commercial issues in fresh mushrooms and mushroom-based products sold at retail in Tuscany region. Italian Journal of Food Safety, 11(3), 10044. https://pmc.ncbi.nlm.nih.gov/articles/PMC9472285/ ↩︎
  65. El Sheikha, A. F., & Hu, D.-M. (2018). How to trace the geographic origin of mushrooms? Trends in Food Science & Technology, 78, 292–303. https://doi.org/10.1016/j.tifs.2018.06.008 ↩︎
  66. https://nutraceuticalbusinessreview.com/sourcing-quality-functional-mushroom-ingredients-part-ii ↩︎
  67. https://eur-lex.europa.eu/eli/reg/2002/178/oj/eng ↩︎
  68. https://www.ifc.org/content/dam/ifc/doc/2023/the-basics-of-food-traceability-ifc-2023.pdf ↩︎
  69. Łysakowska, P., Sobota, A., & Wirkijowska, A. (2023). Medicinal mushrooms: Their bioactive components, nutritional value and application in functional food production—A review. Molecules, 28(14), 5393. pmc.ncbi.nlm.nih.gov ↩︎
  70. PitchBook ↩︎
  71.  https://nutraceuticalbusinessreview.com/kaapa-biotech-functional-mushroom-900k-scaling-investment ↩︎
  72. https://www.edibleplanetventures.com/post/revolutionizing-wellness-spacegoods-seed-funding-success-and-its-impact-on-the-future-of-health ↩︎
  73. https://straitsresearch.com/report/functional-mushroom-market ↩︎
  74. https://www.herbaltreasure.com/differences-in-regulatory-standards-for-dietary-supplements-and-functional-foods-fda-vs-eu/ ↩︎